|Email Newsletters from Pharmaceutical Technology and Pharmaceutical Technology Europe|
News from Europe's pharmaceutical manufacturing industry coupled with upcoming events, and exclusive articles and interviews from industry experts.
Industry Briefs: June 25, 2012
Bristol-Myers Squibb and Pfizer have received a Complete Response Letter from FDA for Eliquis (apixaban), for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Read More
Impax Laboratories and Tolmar have entered into a multiproduct agreement for the development, supply, and distribution of generic topical prescription drug products. Read More
FDA has issued Janssen R&D a Complete Response Letter for Xarelto (rivaroxaban) for the reduction of secondary cardiovascular events in patients with acute coronary syndrome Read More
PharmaNet/i3 has launched PharmaNet/i3 Strategic Resourcing, a new provider of staffing and functional service provider services. Read More
Quotient Clinical and Capsugel have announced a collaboration for the development and clinical assessment of lipid-based formulations. Read More
Takeda North America has changed its name to Takeda Pharmaceuticals USA. Read More
WIL Research Company has selected Thermo Fisher Scientific’s Q Exactive mass spectrometer systems to expand its capabilities for regulated bioanalysis, drug discovery, metabolism, and structural identification services.
Takeda has announced a new assignment of directors, the appointment of corporate officers and a change of senior leadership. Key appointments include Masato Iwasaki as director and senior vice-president of Pharmaceutical Marketing, and Deborah Dunsire as director, president, and CEO of the company’s subsidiary Millennium Pharmaceuticals. Read More